Dr. Naga Suresh Veerapu | Department of Life Sciences


Dr. Naga Suresh
Associate Professor
Department of Life Sciences
School of Natural Sciences (SNS)
A321E, Shiv Nadar University
Gautam Buddha Nagar Uttar Pradesh
Profile Summary 

Dr. Naga Suresh Veerapu earned Ph.D. from AIIMS, New Delhi in the area of Molecular Medical Microbiology in 2005. He worked on rapid molecular diagnosis of MDR-TB. In 2006, he joined Dr. Rehermann’s laboratory, Liver Diseases Section, NIDDK, NIH and had worked on HCV persistence and infectious nature of persisted HCV. Before joining Shiv Nadar University Dr. Veerapu moved to Dr. Andrea Branch laboratory, MSSM, NY; along with Dr. Frances Eng, Dr. Veerapu continued working on HCV Core gene alternative translation mechanisms.

Educational Qualifications 
All India Institute of Medical Sciences
Andhra University
Work Experience 
Associate Professor,
Department of Life Sciences, Shiv Nadar University,
I currently work here
Assistant Professor,
Department of Life Sciences, Shiv Nadar University,
Post-doctoral Associate,
Mount Sinai School of Medicine,
Visiting Fellow,
Natonal Institutes of Health,
Teaching & Research Interests: 

Cell culture system for hepatitis viruses and virus-host interactions

  1. Indian Council of Medical Research's J.B. Srivastav Oration Award - 2013: Virology (Awarded in year 2017)
  2. Travel Fellowship to attend 17th International Conference on HCV and Related Viruses, Yokahama, Japan, 2010.
  3. 5-year Visiting Fellowship (2006-2011) from US Government, NIDDK, NIH

Scholarly Activity

Journal Articles

Shalini Soni, Deepak Singh, Rakesh Aggarwal, Naga Suresh Veerapu. Enhanced Replication Capacity of Hepatitis C Virus Increases Resistance to Direct-Acting Antivirals. Journal of General Virology, 2021, 103, no. 2 : 001699.

Khan S, Soni S, Veerapu NS. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Frontiers Cellular and Infection Microbiology, 2020.

Singh D, Soni S, Khan S, Sarangi AN, Yennamalli RM, Aggarwal R, Veerapu NS. Genome-wide mutagenesis of hepatitis C virus reveals genome ability to overcome detrimental mutations. Journal of Virology, 2020; 94. pii: e01327-19.

Agarwal S, Baccam P, Aggarwal R, Veerapu NS. Novel Synthesis and Phenotypic Analysis of Mutant Clouds for Hepatitis E Virus Genotype 1. Journal of Virology, 2018: 30;92(4).

Veerapu NS*, Park SH*, Tully DC, Allen TM. Rehermann B. Infectivity of Trace Amounts of Hepatitis C Virus That Sporadically Reappear After Successful Antiviral Therapy. Journal of Clinical Investigation, 2014, 124:3469-78.

*co-first author Park SH, Veerapu NS, Shin EC, Angélique Biancotto, J. Philip McCoy, Capone S, Folgori A, Rehermann B. Subinfectious Hepatitis C Virus Exposures Suppress T Cell Responses Against Subsequent Acute Infection. Nature Medicine, 2013, 19:1638-42.

Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Sporadic reappearance of minute amounts of HCV RNA after successful therapy stimulates cellular immune responses. Gastroenterology, 2011; 140(2): 676-685. *listed on the cover page of Gastroenterology, Vol 140, No. 2.

Shin EC, Park SH, Demino M, Nascimbeni M, Mihalik K, Major M, Veerapu NS, Heller T, Feinstone SM, Rice CM, Rehermann B. Delayed induction, not impaired recruitment, of specific CD8T cells causes the late onset of acute hepatitis C. Gastroenterology, 2011:; 141(2):686-95.

Suresh N, Singh UB, Gupta C, Arora J, Rana T, Samantaray JC. Rapid detection of rifampin resistant Mycobacterium tuberculosis directly from stained sputum smears using single-tube nested polymerase chain reaction deoxyribonucleic acid sequencing. Diagnostic Microbiology and Infectious Diseases, 2007; 58(2): 217-22.

Suresh N, Arora J, Pant H, Rana T, Singh UB. Spoligotyping of Mycobacterium tuberculosis DNA from Archival Ziehl-Neelsen-stained sputum smears. Journal of Microbiological Methods, 2007; 68(2):291-5

Suresh N, Singh UB, Arora J, Pande JN, Seth P, Samantaray JC. Rapid detection of rifampicin-resistant Mycobacterium tuberculosis by in-house, reverse line blot assay. Diagnostic Microbiology and Infectious Diseases, 2006; 56(2): 133-40.

Suresh N, Singh UB, Arora J, Pant H, Seth P, Sola C, Rastogi N, Samantaray JC, Pande JN. rpoB gene sequencing and spoligotyping of multidrug-resistant Mycobacterium tuberculosis isolates from India. Infection Genetics and Evolution, 2006; 6(6): 474-83.

Arora J, Singh UB, Suresh N, Rana T, Porwal C, Kaushik A, Pande JN. Characterization of predominant Mycobacterium tuberculosis strains from different subpopulations of India. Infection Genetics and Evolution, 2009; 9(5): 832-9.

Singh UB, Arora J, Suresh N, Pant H, Rana T, Sola C, Rastogi N, Pande JN. Genetic biodiversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in India. Infection Genetics and Evolution, 2007; 7(4): 441-8.

Singh UB, Bhanu NV, Suresh VN, Arora J, Rana T, Seth P. Utility of polymerase chain reaction in diagnosis of tuberculosis from samples of bone marrow aspirate. American Journal of Tropical Medicine Hygiene, 2006; 75(5):960-3.

Bhanu NV, Singh UB, Chakraborty M, Suresh N, Arora J, Rana T, Takkar D, Seth P. Improved diagnostic value of PCR in the diagnosis of female genital tuberculosis leading to infertility. Journal of Medical Microbiology, 2005; 54:927-31.

Singh UB, Suresh N, Bhanu NV, Arora J, Pant H, Sinha S, Aggarwal RC, Singh S, Pande JN, Sola C, Rastogi N, Seth P. Predominant tuberculosis spoligotypes, Delhi, India. Emerging Infectious Diseases, 2004; 10(6): 1138-42.


Grant title: Systematic assembly of SARS-CoV-2 full-length and subgenome cDNA clones. Funding agency: DBT; Duration: 1.5 Yrs;
Status: Ongoing

Grant title: Phase II / III clinical trial of an indigenously-developed hepatitis E vaccine and evaluating its immune correlates. Funding agency: BIRAC; Duration: 2.5 Yrs;
Status: Ongoing

Grant title: Host determinants of hepatitis E disease severity, Funding agency: ICMR; Duration: 2-years.
Status: Ongoing

Grant title: Developing novel robust genotype-3 Hepatitis C virus in vitro culture system through bio-selection, Funding agency: DBT; Duration: 3-years.
Status: Completed

Grant title: Exploring Robust In Vitro Hepatitis E Genotype-1 Replication System, Funding agency: SERB, Duration: 3-years.
Status: Completed